uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15
Linkoping Univ, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden..
Linkoping Univ, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden..
Mayo Clin, Dept Mol Neurosci, Jacksonville, FL 32224 USA..
Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA..
Show others and affiliations
2015 (English)In: Chemical Biology and Drug Design, ISSN 1747-0277, E-ISSN 1747-0285, Vol. 86, no 5, 1036-1048 p.Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor.

Place, publisher, year, edition, pages
2015. Vol. 86, no 5, 1036-1048 p.
Keyword [en]
chalcone, deubiquitinase, in silico modeling, inhibitor, lead optimization, proteasome
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-270622DOI: 10.1111/cbdd.12571ISI: 000365404100009PubMedID: 25854145OAI: oai:DiVA.org:uu-270622DiVA: diva2:890235
Available from: 2016-01-01 Created: 2016-01-01 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Gullbo, Joachim

Search in DiVA

By author/editor
Gullbo, Joachim
By organisation
Cancer Pharmacology and Computational MedicineExperimental and Clinical Oncology
In the same journal
Chemical Biology and Drug Design
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 301 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf